JP2011026326A5 - - Google Patents

Download PDF

Info

Publication number
JP2011026326A5
JP2011026326A5 JP2010200674A JP2010200674A JP2011026326A5 JP 2011026326 A5 JP2011026326 A5 JP 2011026326A5 JP 2010200674 A JP2010200674 A JP 2010200674A JP 2010200674 A JP2010200674 A JP 2010200674A JP 2011026326 A5 JP2011026326 A5 JP 2011026326A5
Authority
JP
Japan
Prior art keywords
group
alkyl
hydrogen
alkylcarbonyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010200674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011026326A (ja
Filing date
Publication date
Priority claimed from US10/079,324 external-priority patent/US20030158188A1/en
Priority claimed from US10/364,210 external-priority patent/US7074805B2/en
Application filed filed Critical
Publication of JP2011026326A publication Critical patent/JP2011026326A/ja
Publication of JP2011026326A5 publication Critical patent/JP2011026326A5/ja
Pending legal-status Critical Current

Links

JP2010200674A 2002-02-20 2010-09-08 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物 Pending JP2011026326A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/079,324 US20030158188A1 (en) 2002-02-20 2002-02-20 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US10/364,210 US7074805B2 (en) 2002-02-20 2003-02-11 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003569203A Division JP4614662B2 (ja) 2002-02-20 2003-02-11 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物

Publications (2)

Publication Number Publication Date
JP2011026326A JP2011026326A (ja) 2011-02-10
JP2011026326A5 true JP2011026326A5 (enExample) 2011-11-24

Family

ID=27759931

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003569203A Expired - Fee Related JP4614662B2 (ja) 2002-02-20 2003-02-11 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物
JP2010200674A Pending JP2011026326A (ja) 2002-02-20 2010-09-08 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003569203A Expired - Fee Related JP4614662B2 (ja) 2002-02-20 2003-02-11 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物

Country Status (8)

Country Link
EP (1) EP1478363B1 (enExample)
JP (2) JP4614662B2 (enExample)
AT (1) ATE420644T1 (enExample)
CA (1) CA2476936A1 (enExample)
DE (1) DE60325834D1 (enExample)
ES (1) ES2319886T3 (enExample)
MX (1) MXPA04008073A (enExample)
WO (1) WO2003070247A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE416168T1 (de) * 2002-02-15 2008-12-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
DE60325834D1 (de) * 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
US7183411B2 (en) * 2002-07-12 2007-02-27 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor
EP2426122A1 (en) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylene urea derivative as RAF kinasse inhibitors
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7375126B2 (en) 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
PT1658269E (pt) * 2003-06-12 2009-01-09 Abbott Lab Compostos condensados que inibem o receptor vanilóide de subtipo 1 (vr1)
TW200524909A (en) * 2003-08-05 2005-08-01 Abbott Lab Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
GB0322016D0 (en) * 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
EP1679296A4 (en) 2003-10-14 2007-12-26 Ajinomoto Kk DERIVE ETHERE
EP1678123A1 (en) * 2003-10-15 2006-07-12 Bayer HealthCare AG Tetrahydro-naphthalene and urea derivatives
WO2005044802A2 (en) 2003-11-08 2005-05-19 Bayer Healthcare Ag Tetrahydro-quinolinylurea derivatives as vrl antagonists
KR101042490B1 (ko) * 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(vr1)활성 저해제
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US7402596B2 (en) * 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE102005023943A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
AU2007238071B2 (en) * 2006-04-18 2012-06-07 Abbvie Inc. Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
CA2661898A1 (en) 2006-08-25 2008-02-28 Abbott Laboratories Indazole derivatives that inhibit trpv1 and uses thereof
JP2010513557A (ja) 2006-12-20 2010-04-30 アボット・ラボラトリーズ 疼痛治療のためのtrpv1バニロイド受容体アンタゴニストとしてのn−(5,6,7,8−テトラヒドロナフタレン−1−イル)尿素誘導体および関連化合物
US8093265B2 (en) 2007-03-09 2012-01-10 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
AU2008238250B2 (en) * 2007-04-16 2013-01-24 Grunenthal Gmbh Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals
DE102007018149A1 (de) 2007-04-16 2008-10-23 Grünenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009096701A2 (en) 2008-01-28 2009-08-06 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US8232411B2 (en) 2008-03-20 2012-07-31 Abbott Laboratories Methods for making central nervous system agents that are TRPV1 antagonists
CN101983197B (zh) 2008-04-18 2015-04-22 大熊制药株式会社 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途
JP5438103B2 (ja) 2008-07-02 2014-03-12 アモーレパシフィック コーポレイション バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
WO2015091965A2 (en) * 2013-12-19 2015-06-25 Lanxess Deutschland Gmbh Process for the production of phthalimides
US10450302B2 (en) * 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
CN107033087B (zh) * 2016-02-04 2020-09-04 西华大学 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途
CN105906564B (zh) * 2016-05-05 2018-11-30 海南省药物研究所 化合物、制备方法及其用途
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
PL3541807T3 (pl) 2016-11-16 2022-01-17 H. Lundbeck A/S Krystaliczna postać inhibitora magl
US10696638B2 (en) * 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043694A (en) * 1960-05-23 1962-07-10 Eastman Kodak Co Novel class of 3-indazolinone developing agent
FR1344579A (fr) * 1961-11-23 1963-11-29 Sandoz Sa Nouveaux dérivés de l'indole et leur préparation
JPS5587771A (en) * 1978-12-27 1980-07-02 Teikoku Hormone Mfg Co Ltd 1-phenylisoquinoline derivative
DE3430310A1 (de) * 1984-08-15 1986-02-27 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue dopamin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS62116559A (ja) * 1985-11-18 1987-05-28 Sagami Chem Res Center 4−アシルメチリデン−4,5,6,7−テトラヒドロインド−ル誘導体及びその製造方法
US4788206A (en) * 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
WO1991004027A1 (en) * 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
JPH05504968A (ja) * 1990-03-07 1993-07-29 ローン―プーラン・ロレ・ソシエテ・アノニム グリシンアミド誘導体、その製造及びそれを含む医薬品
GB9307833D0 (en) * 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin
JPH1087629A (ja) * 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
EP1154989B1 (en) * 1999-02-22 2005-12-14 Pacific Corporation Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof
JP2001122895A (ja) * 1999-10-20 2001-05-08 Hamari Chemicals Ltd 新規なオピオイドペプチド誘導体
KR20030010589A (ko) * 2000-03-09 2003-02-05 오노 야꾸힝 고교 가부시키가이샤 인돌 유도체, 그 제조 방법 및 용도
AU2001271357A1 (en) * 2000-06-21 2002-01-02 Dupont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
IL153884A0 (en) * 2000-07-20 2003-07-31 Neurogen Corp Capsaicin receptor ligands
TWI239942B (en) * 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
JP2005501873A (ja) * 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト アミン誘導体
MY138086A (en) * 2001-09-13 2009-04-30 Smithkline Beecham Plc Novel urea derivative as vanilloid receptor-1 antagonist
JP2004339061A (ja) * 2001-09-28 2004-12-02 Takeda Chem Ind Ltd ベンゼン誘導体、その製造法および用途
MXPA04005427A (es) * 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
GB0130550D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel compounds
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
JP2003192659A (ja) * 2001-12-26 2003-07-09 Bayer Ag フェニル尿素誘導体
DE60325834D1 (de) * 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Similar Documents

Publication Publication Date Title
JP2012041349A5 (enExample)
IL186349A0 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
IL192150A (en) Use of 2-amino-2- [4- (3-benzyloxyphenylthio) -2-chlorophyll} ethyl-1,3-propanadiol, or its acceptable medical salt or hydrate, for the preparation or treatment of inflammatory bowel disease
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
IL221573A (en) Imidazoquinolines and their use in the preparation of drugs for the treatment of proliferative and inflammatory and obstructive pulmonary diseases
ZA200701584B (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
JP2007077157A5 (enExample)
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
JP2011526924A5 (enExample)
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
DK2533050T6 (da) Behandlingsmuligheder ved Fabrys sygdom
IL206039A0 (en) Pharmaceutically acceptable salts of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7, 8-dihydro-9h-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate and their use in therapy
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
JP2010525056A5 (enExample)
DK2155758T3 (da) Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
JP2010536849A5 (enExample)
PL1817282T3 (pl) Pochodne kwasu fenoksyoctowego użyteczne do leczenia chorób układu oddechowego
ATE448219T1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
JP2006528617A5 (enExample)
SI1937633T1 (sl) Derivati bifeniloksiocetne kisline za zdravljenje respiratorne bolezni
GEP20094826B (en) 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
JP2008502694A5 (enExample)
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung